List view / Grid view

Dave Elder

 

The importance of particle size analysis

Particle size reduction is a fast and cost-effective answer to…

3 January 2018 | By , , ,

Particle size reduction is a fast and cost-effective answer to increasing the exposure of poorly soluble oral drugs by increasing surface area and thereby improving dissolution rate. This approach will only work for DCS IIa1 drugs where dissolution rate is the rate-limiting factor for absorption. This may be applicable to…

Modernising the supply chain using continuous manufacturing

When the United States Food and Drug Administration (FDA) called…

15 November 2017 | By , ,

When the United States Food and Drug Administration (FDA) called for a shakeup of pharmaceutical production in 2002 it recommended the early adoption of technological advances and the application of modern quality management techniques. It believed that this would make manufacturing processes more robust and improve product quality.1

Design, formulation and manufacture of film-coated drug products

Film coating is a common step in tablet manufacture that…

25 October 2017 | By

Film coating is a common step in tablet manufacture that can be used to improve product appearance, organoleptic properties, or to facilitate swallowing. Functional film coats can also be used as a part of the product’s stabilisation strategy and to modify or delay drug release.

Ingredients In-Depth Focus 2017

In this issue Dave Elder discusses issues around the manufacture…

23 October 2017 | By

In this issue Dave Elder discusses issues around the manufacture of film coatings and Adeyinka Aina and colleagues consider the potential medicinal uses and efficacy of the flavonoids epigallocatechin and epicatechin, which can be extracted from the Spondias mombin plant.

Continuous manufacturing: regulatory and quality assurance challenges

During 2002, the United States Food and Drug Administration (FDA)…

22 August 2017 | By , ,

During 2002, the United States Food and Drug Administration (FDA) requested rationalisation and modernisation of the manufacturing base for pharmaceutical production. This was in the hope that modernising the supply chain would enhance the robustness of manufacturing processes, thereby reducing product failures and, importantly, significantly enhancing product quality.1 The FDA’s…

Send this to a friend